▲ Aulbio diabetes treatment production line site (Photo = Courtesy of Owlbio)
[메디컬투데이=김준수 기자] Aulbio announced on the 20th that it will participate in the Drug Release Control Society (CRS) held in Las Vegas from July 24th to 28th and present the non-clinical research results of the AUL001 (Exenatide) Diabetes Project.
The Controlled Release Society (CRS) is a society where the latest drug delivery technologies are presented. At this CRS conference, non-clinical research results of the AUL001 Diabetes Project, which has successfully completed non-clinical trials and is entering the clinical trial phase, will be presented. AUL001 is a diabetes treatment that administers Bidurian (Exenatide), a once-a-week administration product of AstraZeneca, once a month, and improves the convenience of patients.
Dr. Kim Cheong-ju, who is in charge of research and development, said, “AUL001 is a diabetes treatment developed with Owl Bio’s proprietary platform technology. It was administered to diabetic rats and the blood concentration of the drug was checked. “In addition, it was confirmed that a single administration effectively and stably reduced blood sugar and HbA1c for a month, and furthermore, had an effect of reducing weight.”
“This can be applied to other GLP-1 receptor agonists and GLP-1/GIP dual receptor agonists of OWL Bio, and will ultimately improve the quality of life of diabetic and obese patients,” he explained.
On the other hand, OWL Bio has a platform technology that loads a high-capacity desired therapeutic ingredient into an ultra-fine microsphere drug delivery system. Currently, Aulbio is developing new drugs for diabetes and obesity, AUL001 (Exenatide), AUL009 (Semaglutide), and AUL016 (Terzepatide), which dramatically reduce the number of administrations.
Reporter Kim Junsu of Medical Today ([email protected])
[저작권자ⓒ 메디컬투데이. 무단전재-재배포 금지]
2023-07-20 09:40:00
#AulBio #presents #results #nonclinical #research #persistent #diabetes #treatment #International #Conference #CRS
